Julie Switzky

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Georgina V. Long, Uwe Trefzer, Michael A. Davies et al. · The Lancet Oncology · 2012 · 908 citations

Medicine, Oncology, Pharmacology +12

Interim results of phase II study BRF113928 of dabrafenib in <i>BRAF</i> V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

David Planchard, Julien Mazières, Gregory J. Riely et al. · Journal of Clinical Oncology · 2013 · 109 citations

Medicine, Oncology, Pharmacology +15

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

Gerald S. Falchook, Seth Rosen, Patricia LoRusso et al. · Clinical Cancer Research · 2019 · 79 citations

Medicine, Oncology, Pharmacology +10

Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites

Danièle Ouellet, Ekaterina Gibiansky, Cathrine Leonowens et al. · The Journal of Clinical Pharmacology · 2014 · 69 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus <i>nab</i>-Paclitaxel and Gemcitabine in Advanced Solid Tumors

Gregory L. Beatty, Safi Shahda, Thaddeus Beck et al. · The Oncologist · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacology +16